Compare ADMA Biologics Inc (ADMA) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs ProShares Ultra Gold ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while ProShares Ultra Gold ETF trades at $44.64. Which is the better fit depends on your goals.
| ADMA | UGL | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $85.62 |
52-Week Low | $7.60 | $33.59 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
UGL trades at $47.09, up 2.04% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights strong central bank gold buying and analyst optimism for gold prices, which may indirectly influence gold-related equities.
The outlook is cautious due to bearish technicals and absent financial data. Risks include gold price volatility and macroeconomic factors. Investors should await earnings reports for fundamental insights, as current data is insufficient for a clear investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
